IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bordeaux Cedex, France, 33076
- Research Site
-
Villejuif, France, 94805
- Research Site
-
-
-
-
-
Barcelona, Spain, 8035
- Research Site
-
Madrid, Spain, 28027
- Research Site
-
-
-
-
-
Lausanne, Switzerland, 1011
- Research Site
-
-
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult subjects; age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Subjects diagnosed with advanced solid tumors.
- For Part 1 and Part 2 (IPH5201 in monotherapy or combined with durvalumab):Subjects must be refractory to standard therapy or for which no standard therapy exists.
- For Part 3 (IPH5201 combined with durvalumab and oleclumab): Subjects must have received and radiologically progressed on 1 prior line of systemic therapy for metastatic pancreatic ductal adenocarcinoma.
- Subjects must have at least 1 measurable lesion according to RECIST v1.1.
- Subjects must provide tumor specimens .
Exclusion Criteria:
- Receipt of any conventional or investigational anticancer therapy (anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies) within 21 days of the planned first dose.
- Receipt of agents targeting CD73, CD39, or adenosine receptors.
- Concurrent enrollment in another therapeutic clinical study.
Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent.
- No toxicity leading to permanent discontinuation of prior IO therapy
- Subjects must not have required the use of additional immunosuppression other than corticosteroids
- Active or prior documented autoimmune or inflammatory disorders within the past 5 years
Cardiac and vascular criteria:
- Presence of myocardial infarction or unstable angina , or stroke, within 6 months.
- Congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension
- History of severe hypertension
- History of any grade of blood clot within 6 months
- Active infection, including tuberculosis; hepatitis B virus (HBV); hepatitis C virus (HCV); or human immunodeficiency virus (HIV)
- Uncontrolled illness including certain lung diseases, uncontrolled diabetes, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study.
- Other invasive malignancy within 2 years.
- Major surgery within 28 days prior to first dose
- Female subjects who are pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IPH5201 monotherapy dose escalation
IPH5201 monotherapy
|
Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
|
|
Experimental: IPH5201 dose escalation with durvalumab
IPH5201 plus durvalumab
|
Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
Durvalumab Q3W for a maximum of 2 years
|
|
Experimental: IPH5201 dose escalation with durvalumab + oleclumab
IPH5201 plus durvalumab and oleclumab
|
Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
Durvalumab Q3W for a maximum of 2 years
Oleclumab Q3W for a maximum of 2 years
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events as a measure of safety
Time Frame: From time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months
|
The primary endpoint is safety as assessed by the presence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs).
|
From time of informed consent through treatment period and including the follow-up 12 weeks after last dose of investigational product, approximately 7 months
|
|
Incidence of clinically significant laboratory values as a measure of safety
Time Frame: From time of informed consent through 12 weeks after the last dose of investigational product, approximately 7 months
|
Number of subjects with clinically significant laboratory values from baseline including blood counts, liver, kidney and pancreas tests, electrolytes, and blood clotting.
|
From time of informed consent through 12 weeks after the last dose of investigational product, approximately 7 months
|
|
Incidence of clinically significant electrocardiogram (ECG) abnormalities as a measure of safety
Time Frame: From time of informed consent through treatment period and including the follow-up period 12 weeks after last dose of investigational product, approximatley 7 months
|
12 lead ECGs will be measured to identify clinical significant abnormalities including ECGs that demonstrate a QTcF value >500ms, 2 additional 12-lead ECGs should be obtained over a 30 minute time period to confirm prolongation based on the average QTcF value
|
From time of informed consent through treatment period and including the follow-up period 12 weeks after last dose of investigational product, approximatley 7 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
OR (Objective Response; Response evaluation criteria in solid tumors [RECIST] v1.1)
Time Frame: From time of consent until date of first documented disease progression (approximately 4 months)
|
Evaluate the primary antitumor activity of IPH5201 monotherapy or in combination with durvalumab +/- oleclumab (disease control)
|
From time of consent until date of first documented disease progression (approximately 4 months)
|
|
DC (Disease Control; RECIST 1.1)
Time Frame: From time of consent until date of first documented disease progression (approximately 4 months)
|
Evaluate the primary antitumor activity of IPH5201 with durvalumab +/- oleclumab (disease control)
|
From time of consent until date of first documented disease progression (approximately 4 months)
|
|
Half-life of IPH5201
Time Frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
To characterize the pharmacokinetics of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab
|
From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
|
Maximum serum concentration (Cmax) of IPH5201
Time Frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
To characterize the pharmacokinetics of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab
|
From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
|
Area under the curve (AUC) of IPH5201
Time Frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
To characterize the pharmacokinetics of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab
|
From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
|
Serum trough concentrations (durvalumab)
Time Frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
To determine the pharmacokinetics of durvalumab when administered in combination with IPH5201+/- oleclumab
|
From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
|
Serum trough concentrations (oleclumab)
Time Frame: From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
To determine the pharmacokinetics of oleclumab in combination with durvalumab and IPH5201
|
From start of treatment through Cycle 6 (21 day cycle, approximately 5 months)
|
|
Incidence of antidrug antibodies (IPH5201)
Time Frame: From start of treatment until 90 days after end of treatment (approximately 7 months)
|
To determine the immunogenicity of IPH5201 as monotherapy and in combination with durvalumab ± oleclumab
|
From start of treatment until 90 days after end of treatment (approximately 7 months)
|
|
Incidence of antidrug antibodies (durvalumab)
Time Frame: From start of treatment until 90 days after end of treatment (approximately 7 months)
|
To determine the immunogenicity of durvalumab in combination with IPH5201 ± oleclumab
|
From start of treatment until 90 days after end of treatment (approximately 7 months)
|
|
Incidence of antidrug antibodies (oleclumab)
Time Frame: From start of treatment until 90 days after end of treatment (approximately 7 months)
|
To determine the immunogenicity of oleclumab in combination with IPH5201 + durvalumab
|
From start of treatment until 90 days after end of treatment (approximately 7 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D6770C00001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.